May 8 |
Immuneering reports Q1 results
|
May 7 |
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
|
May 7 |
We Think Immuneering (NASDAQ:IMRX) Needs To Drive Business Growth Carefully
|
May 6 |
Immuneering Recognizes Melanoma Awareness Month
|
Apr 9 |
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
|
Apr 3 |
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
|
Mar 27 |
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
|
Mar 21 |
Immuneering Director Acquires 7.5% More Stock
|
Mar 19 |
Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone
|
Mar 18 |
Immuneering stock rebounds 34% following last week's selloff
|